^
    BIOMARKER:

    KRAS mutation

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog




    Show legend

    Include preclinical:
    Non Small Cell Lung Cancer
    Colorectal Cancer
    Lung Adenocarcinoma
    Acute Myelogenous Leukemia
    Multiple Myeloma
    Ovarian Cancer
    Lung Non-Squamous Non-Small Cell Cancer
    Endometrial Cancer
    Thyroid Gland Medullary Carcinoma
    Pancreatic Cancer
    Pancreatic Ductal Adenocarcinoma
    Lung Cancer
    Melanoma
    Pancreatic Adenocarcinoma
    Breast Cancer
    Rectal Cancer
    Chronic Myelomonocytic Leukemia
    Juvenile Myelomonocytic Leukemia
    Thyroid Gland Anaplastic Carcinoma
    Cholangiocarcinoma
    Acute Lymphocytic Leukemia
    Thyroid Gland Carcinoma
    Childhood B Acute Lymphoblastic Leukemia
    Bladder Cancer
    Biliary Tract Cancer
    Solid Tumor
    Squamous Cell Carcinoma of Head and Neck
    Colon Cancer
    Colorectal Adenocarcinoma
    Oral Cancer
    Gastric Cancer
    Hairy Cell Leukemia
    Mesothelioma
    cabozantinib capsule
    trametinib
    binimetinib
    VS-6766
    TVB-2640
    bevacizumab + atezolizumab
    bevacizumab + PCM-075
    cobimetinib + RG7440
    BGB-283
    gefitinib
    bevacizumab + RGX-202
    selinexor
    BAL3833
    CYAD-101
    eFT226
    abemaciclib
    LY3009120
    venetoclax + palbociclib
    KPT-8602
    selumetinib
    bevacizumab
    nivolumab
    regorafenib
    venetoclax + cobimetinib
    cobimetinib + RMC-4630
    erlotinib
    cetuximab + avelumab
    durvalumab + tremelimumab
    RGX-202
    pembrolizumab + abemaciclib
    atezolizumab + cobimetinib
    CH4987655
    afatinib + selumetinib
    irinotecan + metformin
    pembrolizumab + INCB024360
    momelotinib
    pembrolizumab + selinexor
    anlotinib
    sunitinib
    pemetrexed
    VS-6766 + VS-6063
    sintilimab
    bevacizumab + cetuximab
    CB-228 + CB-839
    U3-1402
    palbociclib + binimetinib
    HDA + azacitidine
    gemtuzumab ozogamicin
    cetuximab + selumetinib
    AGEN2034 + AGEN1181
    avelumab
    erlotinib + binimetinib
    tislelizumab
    ABBV-400
    pembrolizumab + BGB324
    PDR001 + ERAS-254
    decitabine
    CBS9106
    trametinib + pazopanib
    trametinib + daratumumab + pomalidomide
    nivolumab + rigosertib
    bevacizumab + trifluridine/tipiracil
    pembrolizumab + trametinib
    ASN007
    ASN007 + ERAS-601
    pembrolizumab
    lenzilumab
    trifluridine/tipiracil
    RG6185
    gilteritinib
    Immunotherapy
    HMG-CoA reductase inhibitor + oxaliplatin
    GS-9973
    venetoclax
    cetuximab
    PD-L1 inhibitor
    EGFR inhibitor
    venetoclax + midostaurin
    venetoclax + gilteritinib
    venetoclax + sorafenib
    osimertinib
    ceritinib
    ensartinib
    sotorasib
    ivosidenib
    panitumumab
    MEK inhibitor
    RAD
    anlotinib + APL-502
    toripalimab-tpzi
    durvalumab
    KRAS inhibitor
    SOXIRI
    gemcitabine + albumin-bound paclitaxel
    HIA
    Angiogenesis inhibitor
    trastuzumab + pertuzumab
    PD1 inhibitor
    VRD
    vemurafenib
    FASN inhibitor
    ADX-1612
    GDC-0980
    trametinib + ABT 263
    trametinib + KRT-232
    cobimetinib
    bevacizumab + olaparib
    GDC-0941
    trametinib + BI 1701963
    rigosertib
    trametinib + repotrectinib
    olaparib + APG-1387
    trametinib + dasatinib
    JSI-1187
    EPZ015666
    PD-0325901 + BGB-283
    MTI-31
    CB-228
    PF-05212384 + PD-0325901
    PF-05212384
    dasatinib + selumetinib + RTB101
    sirolimus
    CI-1040 + PI-103
    selumetinib + MK-2206
    SCH772984
    JQ-1
    AGK2
    LY294002
    PD-0325901
    AZD4785
    bortezomib
    palbociclib + CR-1-31-B
    neratinib
    palbociclib
    cetuximab + trametinib
    GC-1118A
    RTB101 + GC-1118A
    BMS-754807
    SY-5609
    ABT 263 + AZD8055
    NG25
    FL118
    cetuximab + dasatinib
    trametinib + palbociclib
    trastuzumab + neratinib
    dasatinib + RG7440
    CI-1040
    VS-6766 + BGB324
    sunitinib + RG7440
    RTB101 + RAF265
    erlotinib
    cobimetinib + RG6185
    dasatinib + MK-2206
    SCH772984 + AZD8186
    afatinib
    RG7440
    SHP099
    alpelisib + ribociclib
    SHP099 + SX-682
    GZ17-6.02
    RMC-6236
    dacomitinib
    IK-930
    ERAS-601
    JZP815
    KIN-2787
    palbociclib + ASN007
    talazoparib
    CDK4 inhibitor + ERK1 inhibitor
    MM-121
    sotorasib + IMM-1-104
    hexachlorophene
    MCLA-158
    selumetinib + KRT-232
    BMF-219
    OMO-103
    BI 894999 + LNP3794
    PTPN11 inhibitor + ERK inhibitor
    RGT-018
    VBI-002
    tepotinib
    SJ-C1044
    SAR408701
    trametinib + CEP-701
    trametinib + midostaurin
    BI-3406 + MEK inhibitor
    BI-3406